Alpha Cognition Surpasses Expectations with Impressive Growth in 2Q26

Alpha Cognition Inc. has reported a remarkable 71% increase in net product revenue for 2Q26, signaling strong demand for its product, ZUNVEYL. Despite slower payer implementation, the company achieved significant progress in both prescriptions and facility adoption, setting the stage for continued growth.